ASTH (Astrana Health Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ASTH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-09 | Brandon Sim | CEO and President | F | — | — |
| 2026-09-08 | Chandan Basho | COO and CFO | F | — | — |
| 2026-09-01 | Mitchell W Kitayama | Director | D | — | — |
| 2026-08-18 | David Schmidt | Director | MIXED | — | — |
| 2026-08-11 | Glenn Sobotka | — | D | — | — |
| 2026-06-12 | Weili Dai | Director | A | — | — |
| 2026-06-12 | Matthew Mazdyasni | Director | A | — | — |
| 2026-06-12 | Mitchell W Kitayama | Director | A | — | — |
| 2026-06-12 | David Schmidt | Director | A | — | — |
| 2026-06-12 | John Chiang | Director | A | — | — |
| 2026-06-12 | Linda Dong | Director | A | — | — |
| 2026-05-18 | Chandan Basho | COO and CFO | F | — | — |
| 2026-04-15 | Chandan Basho | COO and CFO | F | — | — |
| 2026-04-08 | Kenneth T. Sim | Executive Chairman | A | — | — |
| 2026-04-08 | Brandon Sim | CEO and President | A | — | — |
| 2026-04-08 | Thomas S. Lam | Director | A | — | — |
| 2026-04-03 | Dinesh M. Kumar | Chief Medical Officer | MIXED | — | — |
| 2026-04-03 | Chandan Basho | COO and CFO | F | — | — |
| 2026-03-30 | Glenn Sobotka | Chief Accounting Officer | F | — | — |
| 2026-03-09 | Dinesh M. Kumar | Chief Medical Officer | F | — | — |
| 2026-03-09 | Chandan Basho | COO and CFO | F | — | — |
| 2026-03-09 | Thomas S. Lam | Director | F | — | — |
| 2026-02-03 | Brandon Sim | CEO and President | M | — | — |
| 2026-01-27 | Dinesh M. Kumar | Chief Medical Officer | F | — | — |
| 2026-01-15 | David Schmidt | Director | MIXED | — | — |
| 2026-01-05 | Dinesh M. Kumar | Chief Medical Officer | F | — | — |
| 2025-12-10 | Thomas S. Lam | Director | MIXED | — | — |
| 2025-11-13 | Kenneth T. Sim | Executive Chairman | M | — | — |
| 2025-11-12 | Matthew Mazdyasni | Director | M | — | — |
| 2025-11-12 | Mitchell W Kitayama | Director | M | — | — |
| 2025-11-05 | Linda Marsh | Director | MIXED | — | — |
| 2025-10-06 | Chandan Basho | COO and CFO | F | — | — |
| 2025-09-15 | Mitchell W Kitayama | Director | MIXED | — | — |
| 2025-09-09 | Dinesh M. Kumar | Chief Medical Officer | F | — | — |
| 2025-09-09 | Chandan Basho | COO and CFO | F | — | — |
| 2025-09-03 | David Schmidt | Director | MIXED | — | — |
| 2025-08-14 | John Chiang | Director | MIXED | — | — |
| 2025-07-02 | Dinesh M. Kumar | Chief Medical Officer | F | — | — |
| 2025-06-13 | David Schmidt | Director | A | — | — |
| 2025-06-13 | Matthew Mazdyasni | Director | A | — | — |
| 2025-06-13 | Weili Dai | Director | A | — | — |
| 2025-06-13 | John Chiang | Director | A | — | — |
| 2025-06-13 | Mitchell W Kitayama | Director | A | — | — |
| 2025-06-13 | Linda Marsh | Director | A | — | — |
| 2025-06-06 | Dinesh M. Kumar | Chief Medical Officer | F | — | — |
| 2025-05-19 | Chandan Basho | COO and CFO | F | — | — |
| 2025-04-30 | Dinesh M. Kumar | Chief Medical Officer | F | — | — |
| 2025-04-16 | Chandan Basho | COO and CFO | F | — | — |
| 2025-04-03 | Chandan Basho | COO and CFO | F | — | — |
| 2025-03-28 | Glenn Sobotka | Chief Accounting Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Executive Chairman | 6,872,209 | — |
| — | Director | 6,598,459 | — |
| — | 10%+ Owner | 6,132,802 | — |
| — | CEO and President | 1,497,685 | — |
| — | Chief Medical Officer | 177,655 | — |
| — | COO and CFO | 157,820 | — |
| — | Director | 97,133 | — |
| — | Director | 56,019 | — |
| — | Director | 39,288 | — |
| — | Director | 35,373 | — |
| — | Director | 24,337 | — |
| — | Director | 18,188 | — |
| — | Chief Accounting Officer | 17,520 | — |
| — | Chief Accounting Officer | 2,246 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ASTH quote page; the site-wide leaderboard is on the insider transactions hub.